Ipsen tries again in Parkinson’s disease with $363m IRLAB dealFrench drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine Share XIpsen tries again in Parkinson’s disease with $363m IRLAB dealhttps://pharmaphorum.com/news/ipsen-tries-again-in-parkinsons-disease-with-363m-irlab-deal/
